medigraphic.com
A partir del año 2010, la Revista Oficial del INER cambió a NCT (Neumología y Cirugía de Tórax)

 Ver actualización

2008, Number 3

<< Back Next >>

Rev Inst Nal Enf Resp Mex 2008; 21 (3)

The “New” bronchopulmonary dysplasia. Part I

Lule MMS, Guzmán GAM, Sierra VMP, Torres RJD

Language: Spanish
References: 55
Page: 221-234
PDF size: 138.82 Kb.


ABSTRACT

In 1967, Northway et ál, published the "classical" description of the bronchopulmonary dysplasia (BPD). Changes occurred to this entity in the last four decades motivated the National Heart, Lung, and Blood Institute to define updated criteria of the "new" BPD. Emphasis was put in prematurely born before 32 gestational weeks, since normal alveolar and vascular development is interrupted, and in the early therapeutic use of supplementary oxygen, which joined to the metabolic immaturity, favors the production of reactive oxygen species that provoke pulmonary damage in the "new" BPD. Owing to continuing advances in technology and research, survival of extremely premature babies (‹ 1,000 g) is increasing, which leads to a higher number of children with chronic sequelae of BPD. Therefore, the objective of the present work was to present a review of the current knowledge of physiopathogenic and therapeutic changes occurred in this disease.


REFERENCES

  1. Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. N Engl J Med 2000;342:1500-1507.

  2. Bancalari E, González A. Clinical course and lung function abnormalities during development of neonatal chronic lung disease. In: Bland RD, Coalson JJ, editors. Chronic lung disease in early infancy. New York: Marcel Dekker; 2000.p. 41-64.

  3. Shennan at, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics 1988;82:527-532.

  4. Tschanz SA, Burri PH. Postnatal lung development and its impairment by glucocorticoids. Pediatr Pulmonol Suppl 1997;16:247-249.

  5. Tschanz SA, Damke BM, Burri PH. Influence of postnatally administered glucocorticoids on rat lung growth. Biol Neonate 1995;68:229-245.

  6. Committee on Fetus and Newborn. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 2002;109:330-338.

  7. Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967;276:357-368.

  8. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;163:1723-1729.

  9. Davis PG, Thorpe K, Roberts R, Schmidt B, Doyle LW, Kirpalani H; and Trial Indomethacin Prophylaxis in Preterms Investigators. Evaluating "old" definitions for the "new" bronchopulmonary dysplasia. J Pediatr 2002; 140: 555-560.

  10. Bhandari A, Panitch HB. Pulmonary outcomes in bronchopulmonary dysplasia. Semin Perinatol 2006;30:219-226.

  11. Furuya ME. Displasia broncopulmonar. En: Hernández E, Furuya ME, editores. Enfermedades respiratorias pediátricas. México: El manual moderno;2002.p. 361-367.

  12. Abman SH, Bancalari E. The Aspen Conference on bronchopulmonary dysplasia June 29-July 4, 1986 presented by the institute for pediatric medical education. Pediatr Pulmonol 1987;3:185-196.

  13. Aylward GP, Pfeiffer SI, Wright A, Verhulst SJ. Outcome studies of low birth weight infants published in the last decade: a meta-analysis. J Pediatr 1989;115: 515-520.

  14. Farrell PM, Palta M. Bronchopulmonary dysplasia: In: Farrell PM, Taussig LM, editors. Bronchopulmonary dysplasia and related chronic respiratory disorders. Report of the 90th Ross Conference on Pediatric Research, Columbus, Ohio. Ross Laboratories, 1986.

  15. Barrios R. Embriología y anatomía del parénquima pulmonar. En: Cano VF, Baltazares LE, Ibarra PC, editores. Enfermedades del aparato respiratorio. México: Méndez Editores;2008.p. 13-36.

  16. Lule MMS, Salcedo ChM, Rivas HCA, et ál. Malformaciones congénitas broncopulmonares. En: Cano VF, Baltazares LE, Ibarra PC, editores. Enfermedades del aparato respiratorio. México: Méndez Editores; 2008.p. 139-160.

  17. Olivares CIM, Guzmán GAM, Medina NR, Hicks GJJ. Especies reactivas del oxígeno (ERO). En: Hicks GJJ, editor. Bioquímica. México: McGraw Hill; 2002.p. 689-708.

  18. Davis JM, Rosenfeld WN, Sanders RJ, Gonenne A. Prophylactic effects of recombinant human superoxide dismutase in neonatal lung injury. J Appl Physiol 1993;74:2234-2241.

  19. Davis JM, Parad RB, Michele T, Allred E, Price A, Rosenfeld W; and North American Recombinant Human CuZnSOD Study Group. Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase. Pediatrics 2003;111:469-476.

  20. Chappell LC, Seed PT, Briley AL, et ál. Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomized trial. Lancet 1999; 354:810-816.

  21. Tremblay LN, Slutsky AS, Dreyfuss D, Saumon G. Ventilator-induced lung injury: mechanisms and clinical correlates. In: Marini JJ, Slutsky AS, editors. Physiological basis of ventilatory support. New York: Marcel Sekker; 1998.p. 395-451.

  22. Dreyfuss D, Saumon G. Ventilator-induced lung injury: lessons from experimental studies. Am J Respir Crit Care Med 1998;157:294-323.

  23. Muscedere JG, Mullen JB, Gan K, Slutsky AS. Tidal ventilation at low airway pressures can augment lung injury. Am J Respir Crit Care Med 1994;149:1327-1334.

  24. Adam EW, Harrison MC, counsell SJ, et ál. Increased lung water and tissue damage in bronchopulmonary dysplasia. J Pediatr 2004;145:503-507.

  25. Taskar V, John J, Evander E, Robertson B, Jonson B. Surfactant dysfunction makes lungs vulnerable to repetitive collapse and reexpansion. Am J Respir Crit Care Med 1997;155:313-320.

  26. Gattinoni L, Bombino M, Pelosi P, et ál. Lung structure and function in different stages of severe adult respiratory distress syndrome. Jama 1994;271:1772-1779.

  27. Brun-Buisson C, Minelli C, Bertolini G, et ál, and ALIVE Study Group. Epidemiology and outcome of acute lung injury in European intensive care units. Results from the ALIVE study. Intensive Care Med 2004;30:51-61.

  28. Stevenson DK, Wright LL, Lemons JA, et ál. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal research network, January 1993 through December 1994. Am J Obstet Gynecol 1998;179(6 Pt 1):1632-1639.

  29. Leonard CH, Clyman RI, Piecuch RE, Juster RP, Ballard RA, Behle MB. Effect of medical and social risk factors on outcome of prematurity and very low birth weight. J Pediatr 1990;116:620-626.

  30. Evans M, Palta M, Sadek M, Weinstein MR, Peters ME. Associations between family history of asthma, bronchopulmonary dysplasia, and childhood asthma in very low birth weight children. Am J Epidemiol 1998; 148:460-466.

  31. Minoo P, Su G, Drum H, Bringas P, Kimura S. Defects in tracheoesophageal and lung morphogenesis in Nkx2.1(-/-) mouse embryos. Dev Biol 1999;209: 60-71.

  32. Lecart C, Cayabyab R, Buckley S, et ál. Bioactive transforming growth factor-beta in the lungs of extremely low birthweight neonates predicts the need for home oxygen supplementation. Biol Neonate 2000; 77:217-223.

  33. Bhandari A, Bhandari V. Pathogenesis, pathology and pathophysiology of pulmonary sequelae of bronchopulmonary dysplasia in premature infants. Front Biosci 2003;8:e370-e380.

  34. Bhandari V, Gruen JR. The genomics of bronchopulmonary dysplasia. Neoreviews 2007;8:e336-e344.

  35. Morcillo F, Izquierdo I, López JA. Enfermedad pulmonar crónica de la prematuridad. En: Cobos BN, González P-YE, editores. Tratado de neumología infantil. Madrid: Ergon;2003.p. 315-342.

  36. Carlo WA, Stark AR, Wright LL, et ál. Minimal ventilation to prevent bronchopulmonary dysplasia in extremely-low-birth-weight infants. J Pediatr 2002; 141:370-374.

  37. Ferreira PJ, Bunch TJ, Albertine KH, Carlton DP. Circulating neutrophil concentration and respiratory distress in premature infants. J Pediatr 2000;136: 466-472.

  38. Kotecha S. Cytokines in chronic lung disease of prematurity. Eur J Pediatr 1996;155 Suppl 2:S14-S17.

  39. Watterberg KL, Demers LM, Scott SM, Murphy S. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 1996;97:210-215.

  40. Yoon BH, Romero R, Jun JK, et ál. Amniotic fluid cytokines (inter leukin-6, tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia. Am J Obstet Gynecol 1997;177:825-830.

  41. Sehdev HM, Abbasi S, Robertson P, et ál. The effects of the time interval from antenatal corticosteroid exposure to delivery on neonatal outcome of very low birth weight infants. Am J Obstet Gynecol 2004;191: 1409-1413.

  42. Kresch MJ, Clive JM. Meta-analyses of surfactant replacement therapy of infants with birth weights less than 2000 grams. J Perinatol 1998;18:276-283.

  43. Bell EF, Warburton D, Stonestreet BS, Oh W. Effect of fluid administration on the development of symptomatic patent ductus arteriosus and congestive heart failure in premature infants. N Engl J Med 1980;302: 598-604.

  44. Hussain NA, Siddiqui NH, Stocker JT. Pathology of arrested acinar development in postsurfactant bronchopulmonary dysplasia. Human Pathol 1998;29:710-717.

  45. Tammela OK. Appropriate fluid regimens to prevent bronchopulmonary dysplasia. Eur J Pediatr 1995;154 (8 Suppl 3):S15-S18.

  46. Burri PH. Structural aspects of prenatal and postnatal development and growth of the lung. In: McDonald JA, editor. Lung growth and development. New York: Marcel Dekker; 1997.p. 1-35.

  47. Margraf LR, Tomashefski JR Jr, Bruce MC, Dahms BB. Morphometric analysis of the lung in bronchopulmonary dysplasia. Am Rev Respir Dis 1991;143:391-400.

  48. Tomashefski JF Jr, Oppermann HC, Vawter GF, Reid LM. Bronchopulmonary dysplasia: a morphometric study with emphasis on the pulmonary vasculature. Pediatr Pathol 1984;2:469-487.

  49. Jobe AH. The new BPD. Neoreviews 2006;7:e531-e545.

  50. Tepper RS, Morgan WJ, Cota K, Taussig LM. Expiratory flow limitation in infants with bronchopulmonary dysplasia. 1986;109:1040-1046.

  51. Hjalmarson O, Sandberg KL. Lung function at term reflects severity of bronchopulmonary dysplasia. J Pediatr 2005;146:86-90.

  52. Palta M, Sadek-Badawi M, Barnet JH, et ál. Evaluation of criteria for chronic lung disease in surviving very low birth weight infants. Newborn Lung Project. J Pediatr 1998;132:57-63.

  53. Palta M, Sadek-Badawi M, Evans M, Weinstein MR, McGuinnes G. Functional assessment of a multicenter very low-birth-weight cohort at age 5 years. Newborn Lung Project. Arch Pediatr Adolesc Med 2000;154: 23-30.

  54. Thibeault DW, Mabry SM, Ekekezie II, Troug WE. Lung elastic tissue maturation and perturbations during the evolution of chronic lung disease. Pediatrics 2000;106:1452-1459.

  55. McCubbin M, Frey EE, Wagener JS, Tribby R, Smith WL. Large airway collapse in bronchopulmonary dysplasia. J Pediatr 1989;114:304-307.




2020     |     www.medigraphic.com